- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387810
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer (undetermined)
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer:A Prospective, Single-arm, Multicenter, Phase II Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients.
After screening and signing informed consent, patients who met the admission requirements received neoadjuvant therapy with irinotecan liposome II combined with 5-FU/LV and oxaliplatin before surgery (once every 2 weeks, every 2 weeks). After completing 4 cycles of preoperative neoadjuvant therapy, surgical evaluation was performed:
For patients evaluated for radical surgical resection, surgery was performed within 2 to 4 weeks after the end of neoadjuvant therapy, abdominal enhanced CT/MRI was performed within 4 to 6 weeks after surgery, and postoperative adjuvant therapy with irinotecan liposome II combined with 5-FU/LV and oxaliplatin was performed according to the investigator's judgment (once every 2 weeks, a 2-week cycle). After the completion of 4 cycles of postoperative adjuvant therapy, the tumor progression follow-up/survival follow-up stage was entered.
Patients who were assessed as not eligible for radical surgical resection could choose follow-up treatment according to the investigator's judgment, and continue to follow up their survival until withdrawal of informed consent or death.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wenming Wu, doctor
- Phone Number: +86 010-69156053
- Email: doctorwuu@126.com
Study Contact Backup
- Name: +86 010-69156053 Wu, doctor
- Phone Number: +86 010-69156053
- Email: doctorwuu@126.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024.V1 edition), patients with critically resectable pancreatic cancer.
- Have at least one measurable lesion as a target lesion (according to RECIST v1.1);
- Have not received any anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeting, immunotherapy, etc.) or investigational drug therapy;
- ECOG: 0 ~ 1;
- Expected survival ≥3 months;
- Adequate organ and blood function
Exclusion Criteria:
- Pancreatic cancer of non-pancreatic ductal origin includes patients with pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatic blastoma, and solid pseudopapillary tumor
- Severe gastrointestinal dysfunction
- Severe infection occurred within 4 weeks prior to initiation of treatment (CTCAE > Grade 2)
- Blood clotting is abnormal, has a tendency to bleed, or is receiving thrombolytic or anticoagulant therapy
- Have clinical symptoms or diseases of heart that are not well controlled, such as: (1) NYHA grade 2 or above heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction occurred within 6 months; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
- Known allergy to irinotecan liposome II, other liposome products, oxaliplatin, 5-FU, calcium leucovorin, and any component of the above products
- Known peripheral neuropathy (CTCAE≥ Grade 3)
- In the investigator's judgment, subjects had other factors that might have led to their being forced to terminate the study, such as non-adherence to the protocol, other serious medical conditions (including mental illness) requiring combined treatment, clinically significant abnormalities in laboratory test values, or family or social factors that might affect subjects' safety or the collection of trial data
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined treatment group
After screening and signing informed consent, patients who met the admission requirements received 4 cycles of neoadjuvant therapy with irinotecan liposome II combined with 5-FU/LV and oxaliplatin before surgery. Surgery was performed within 2 to 4 weeks after the end of neoadjuvant therapy. 4 to 6 weeks after surgery, 4 cycles of postoperative adjuvant therapy with irinotecan liposome II combined with 5-FU/LV and oxaliplatin was performed according to the investigator's judgment (once every 2 weeks, a 2-week cycle). |
irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks. Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
event free survival
Time Frame: 5 years
|
The time between the date the subject started treatment and the occurrence of tumor progression leading to inoperability, postoperative recurrence/metastasis, or death, whichever occurred first.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: 5 years
|
The time from the start of treatment until death from any cause
|
5 years
|
R0 resection rate
Time Frame: 2 years
|
R0 resection rate, defined as postoperative assessment of R0 resection (complete resection of the tumor, no cancer cells found on the margin of resection under the microscope, no cancer cells remaining under the naked eye or microscope, complete resection of the lesion).
The proportion of subjects.
|
2 years
|
R1 excision rate
Time Frame: 2 years
|
R1 excision rate, defined as postoperative assessment of R1 excision (microscopic residual, removal of all large lesions, submicroscopic margin of cancer).
The proportion of subjects;
|
2 years
|
adverse event
Time Frame: 5 years
|
Adverse events (AE)/Serious Adverse Events (SAE) (as determined by NCI-CTCAE 5.0)
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wenming Wu, doctor, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Oxaliplatin
- Irinotecan
Other Study ID Numbers
- MA-PC-II-010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Resectable Pancreatic Cancer
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Kimberly Perez, MDNovartisTerminatedPancreatic Cancer | Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Fudan UniversityWest China Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Zhejiang... and other collaboratorsRecruitingBorderline Resectable Pancreatic CancerChina
-
Universita di VeronaSuspendedBorderline Resectable Pancreatic CancerItaly
-
Peking Union Medical College HospitalUnknownBorderline Resectable Pancreatic CancerChina
-
Galera Therapeutics, Inc.TerminatedUnresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRTUnited States, France, United Kingdom, Canada
-
Cancer Institute and Hospital, Chinese Academy...Jiangsu HengRui Medicine Co., Ltd.RecruitingBorderline Resectable Pancreatic CancerChina
-
University of Alabama at BirminghamNot yet recruitingBorderline-resectable Pancreatic CancerUnited States
-
Nagoya UniversityActive, not recruitingBorderline Resectable Pancreatic Cancer
Clinical Trials on irinotecan liposome II combined with 5-FU/LV and oxaliplatin
-
CSPC Ouyi Pharmaceutical Co., Ltd.UnknownAdvanced Pancreatic CancerChina
-
Zhejiang UniversityNot yet recruitingResectable Pancreatic Cancer | Neoadjuvant Chemotherapy
-
Uppsala UniversityCompletedGastric Cancer | Peritoneal CarcinomatosisSweden
-
Shanghai Zhongshan HospitalCSPC Ouyi Pharmaceutical Co., Ltd.Recruiting
-
Martin-Luther-Universität Halle-WittenbergRoche Pharma AGCompletedMetastatic Colorectal CancerGermany
-
Fundación de investigación HMSyntax for Science, S.LCompletedLocally Advanced Rectal Cancer (LARC)Spain
-
Hamamatsu UniversityCompletedEsophageal Cancer | Squamous Cell CarcinomaJapan
-
West China HospitalNot yet recruitingMetastatic Colorectal Cancer
-
PfizerCompletedColorectal NeoplasmsAustralia, Canada, United States, New Zealand